Literature DB >> 11719394

Successful allogeneic engraftment of mismatched unrelated cord blood following a nonmyeloablative preparative regimen.

D A Rizzieri1, G D Long, J J Vredenburgh, C Gasparetto, A Morris, T T Stenzel, P Davis, N J Chao.   

Abstract

Reduction in the toxicity of allogeneic transplantation with nonmyeloablative induction regimens has expanded the scope of practice to older and more debilitated patients. However, the limited availability of matched sibling donors requires that alternative donor sources be investigated. Reported here are 2 cases of patients with advanced hematologic malignancies without matched siblings, partially matched family members, or matched unrelated donors who successfully underwent nonmyeloablative conditioning therapy followed by infusion of partially matched, unrelated-donor cord blood cells. The patients are in remission and remain 100% donor as assessed by short tandem repeat analysis of the marrow 6 and 12 months following transplantation.

Entities:  

Mesh:

Year:  2001        PMID: 11719394     DOI: 10.1182/blood.v98.12.3486

Source DB:  PubMed          Journal:  Blood        ISSN: 0006-4971            Impact factor:   22.113


  7 in total

1.  Natural killer cell-enriched donor lymphocyte infusions from A 3-6/6 HLA matched family member following nonmyeloablative allogeneic stem cell transplantation.

Authors:  David A Rizzieri; Robert Storms; Dong-Feng Chen; Gwynn Long; Yiping Yang; Daniel A Nikcevich; Cristina Gasparetto; Mitchell Horwitz; John Chute; Keith Sullivan; Therese Hennig; Debashish Misra; Christine Apple; Megan Baker; Ashley Morris; Patrick G Green; Vic Hasselblad; Nelson J Chao
Journal:  Biol Blood Marrow Transplant       Date:  2010-02-24       Impact factor: 5.742

2.  Advances in cord blood transplants in adults.

Authors:  Phuong L Doan; Nelson J Chao
Journal:  F1000 Med Rep       Date:  2010-02-11

3.  Autologous recovery with protractedly undetectable donor chimerisms can precede stable donor engraftment in a nonmyeloablative cord blood transplant.

Authors:  William Hwang Ying Khee; Patrick Tan Huat Chye; Tan Cheng Hoe; How Gee Fung; Heng Khee Khiang; Goh Yeow Tee
Journal:  Int J Hematol       Date:  2003-07       Impact factor: 2.490

4.  Reduced-intensity allogeneic transplantation using alemtuzumab from HLA-matched related, unrelated, or haploidentical related donors for patients with hematologic malignancies.

Authors:  Junya Kanda; Gwynn D Long; Cristina Gasparetto; Mitchell E Horwitz; Keith M Sullivan; John P Chute; Ashley Morris; Michael Shafique; Zhiguo Li; Nelson J Chao; David A Rizzieri
Journal:  Biol Blood Marrow Transplant       Date:  2013-11-20       Impact factor: 5.742

5.  A novel reduced-intensity umbilical cord blood transplantation using a recombinant G-CSF combined with high-dose Ara-C for active myeloid malignancies.

Authors:  M Gotoh; S Yoshizawa; S Katagiri; T Suguro; M Asano; T Kitahara; D Akahane; S Okabe; T Tauchi; Y Ito; K Ohyashiki
Journal:  Bone Marrow Transplant       Date:  2014-04-14       Impact factor: 5.483

6.  Phase II study of intrabone single unit cord blood transplantation for hematological malignancies.

Authors:  Makoto Murata; Yoshinobu Maeda; Masayoshi Masuko; Yasushi Onishi; Tomoyuki Endo; Seitaro Terakura; Yuichi Ishikawa; Chisako Iriyama; Yoko Ushijima; Tatsunori Goto; Nobuharu Fujii; Mitsune Tanimoto; Hironori Kobayashi; Yasuhiko Shibasaki; Noriko Fukuhara; Yoshihiro Inamoto; Ritsuro Suzuki; Yoshihisa Kodera; Tadashi Matsushita; Hitoshi Kiyoi; Tomoki Naoe; Tetsuya Nishida
Journal:  Cancer Sci       Date:  2017-06-29       Impact factor: 6.716

Review 7.  Haploidentical Hematopoietic Stem Cell Transplantation: Expanding the Horizon for Hematologic Disorders.

Authors:  Mohammad Faizan Zahid; David Alan Rizzieri
Journal:  Adv Hematol       Date:  2016-02-02
  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.